Abstract:Neurotrophic Keratopathy (NK) is not a specific disease entity but a consequence of several conditions with varied aetiopathogenesis, of which a loss or reduction in corneal sensitivity is the hallmark. NK is clinically graded as Mild (stage1), Moderate (stage 2) and Severe (stage 3). The grading helps in understanding severity and planning treatment. Management can be considered in two parts. The first is the management of the underlying condition when active, for example herpes virus keratitis, bacterial ulcers and immune mediated ulcerative keratitis; and the second part, which deals with treatment of the non‐healing epithelial defect, stromal melting with or without vascularization and perforation that remains due to epithelial, stromal and corneal nerve pathology. Management of mild and moderate NK begins with the identification and elimination of any obvious underlying cause such as neuroleptic, antipsychotic, antihistamine and other systemic medications, preservatives in long term topical medications; and treatment of concurrent ocular surface infection. Tear substitutes and anti‐inflammatory agents both steroids and specific immunosuppressors like cyclosporin and lifitegrast should be used early. Antibiotics can be used prophylactically or to treat subclinical or overt infection. Medication with preservatives should be avoided. Prevention of progression to severe (stage 3) NK can be achieved with antiproteases such as citrate, tetracyclines and macrolides. Substrate re‐generating agents like Cacicol and promoters of epithelial regeneration like co‐enzyme Q10 target aspects of the underlying pathology. The introduction of recombinant human nerve growth factor (rh)NGF (Cenegermin/Oxervate) has provided specific therapy that addresses the basic defect related to corneal nerves. Insulin drops are proving to be useful and amniotic membrane extracts/amniotic fluid has also been tried. Autologous and pooled allo serum or plasma drops, which provide a variety of known and unknown factors have also proved useful but may at times aggravate the condition. Usually a combination of two or more of the above are required but rhNGF and insulin hold considerable promise for long term remission. Medical treatment is often augmented with non‐surgical interventions such as bandage contact lens, padding, punctal plugs, botulinum toxin, frost suture and glue. These are primarily designed to deal with exposure, dry eyes and reduce the abrasive effect of lid blinks, to promote healing. Useful surgical procedures include tarsorrhaphy, amniotic and conjunctival grafts, penetrating and lamellar keratoplasty and limbal stem cell transplants. Surgical interventions are designed to augment effects of the non‐surgical interventions, reduce scarring, deal with complications and restore sight. A key principle is that wound healing after any form of surgery or transplant, is poor if the corneal sensations remain impaired or absent.

Establishment of mouse model of neurotrophic keratopathy through TRPV1 neuronal ablation

Preventing and treating neurotrophic keratopathy by a single intrastromal injection of AAV-mediated gene therapy

Histone Methylation Regulates Neutrophil Extracellular Traps to Attenuate Corneal Neovascularization

Impaired healing of cornea incision injury in a TRPV1-deficient mouse

Impaired healing of cutaneous wound in a Trpv1 deficient mouse

A New Treatment for Recalcitrant Neurotrophic Keratopathy of Ocular Graft-Versus-Host Disease with Virus Infection

An experimental model for primary neuropathic corneal pain induced by long ciliary nerve ligation in rats

Temporal Changes of Spinal Transcriptomic Profiles in Mice With Spinal Nerve Ligation.

Chitosan-based thermosensitive hydrogel with long-term release of murine nerve growth factor for neurotrophic keratopathy

TRPV1 + sensory nerves modulate corneal inflammation after epithelial abrasion via RAMP1 and SSTR5 signaling

Keratin8 Deficiency Aggravates Retinal Ganglion Cell Damage under Acute Ocular Hypertension

Characteristics of the ocular surface in neurotrophic keratitis induced by trigeminal nerve injury following neurosurgery

Assessment of corneal nerve regeneration after axotomy in a compartmentalized microfluidic chip model with automated 3D high resolution live-imaging

Sustained Release of Tacrolimus From a Topical Drug Delivery System Promotes Corneal Reinnervation

CGRP Released by Corneal Sensory Nerve Maintains Tear Secretion of the Lacrimal Gland

Medical and surgical management of neurotrophic keratopathy

A Hypothalamic-Controlled Neural Reflex Promotes Corneal Inflammation

TRPV1 Gain-of-function Mutation Impairs Pain and Itch Sensations in Mice

Hydrogel dressings on neurotrophic keratitis in an experimental animal model

NKT cells are critical to initiate an inflammatory response after Pseudomonas aeruginosa ocular infection in susceptible mice.

New, potent, small molecule agonists of tyrosine kinase receptors attenuate dry eye disease